16.4. Disposition , Demographics, and Baseline Characteristics Disposition information will be summarized, including the number s of dosed patients, and patients withdrawn by reason , as well as the reason for discontinuation from treatment . Descriptive information on demographics and basel ine characteristics , including age, sex, weight, height, physical examination, and baseline ECOG score will be provided in a summary table. Summaries will be provided by treatment group and overall for the Safety and Per Protocol population s. 16.5. Primary Efficacy Endpoint and Analysis Safety /tolerability is the primary endpoint for the phase 1b portion of this study . For the phase 2 portion of this study, the primary endpoint for Arm 5 cohorts is ORR and the primary endpoint for Arm 6 cohorts is PFS. Phase 1b: Safety and Tolerability Safety will be measured by the frequency of treatment emergent adverse events ( TEAEs)/serious adverse events (SAE s), including clinically significant (CS) abnormal laboratory parameters, ECGs, PEs, and vitals in patient s receiving at least one dose of HS-110. Phase 2: Objective Response Rate (Arm 5 Cohorts A/B) and Progression Free Survival (Arm 6 Cohorts C/D) For Arm 5 Cohorts A and B, ORR will be defined as the proportion of patients achieving a best overall response of complete response (CR) or partial response (PR) by RECIST 1.1. These response rates will be summarized for each cohort using counts and percentages.